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Breast tumors are heterogeneous including cells with stem cell properties and more differ-
entiated cells. This heterogeneity is reflected into the molecular breast cancer subtypes.
Breast cancer stem cells are resistant to chemotherapy, thus recent efforts are focusing
on identifying treatments that shift them toward a more differentiated phenotype, making
them more susceptible to chemotherapy. We examined whether the drug cisplatin induces
differentiation in breast cancer cell lines that represent different breast cancer subtypes.
We used three cell lines representing triple-negative breast cancers, BT-549 and MDA-MB-
231 (claudin-low), and MDA-MB-468 (basal-like), along with estrogen and progesterone
receptor positive MCF-7 cells (luminal). Cisplatin was applied at 2.5, 5, 10, and 20µM, and
cell viability and proliferation were measured using MTS and BrdU assays, respectively.
The effect of cisplatin on the cellular hierarchy was examined by flow cytometry, immuno-
fluorescence and qRT-PCR. Cisplatin treatment of 10 and 20µM reduced cell viability by
36–51% and proliferation capacity by 36–67%.Treatment with cisplatin resulted in 12–67%
down-regulation of stem cell markers (CD49f, SSEA4) and 10–130% up-regulation of differ-
entiation markers (CK18, SMA, β-tubulin). At the mRNA level, CD49f was down-regulated
whilst β-tubulin was up-regulated in the claudin-low cell lines. SSEA4 protein expression
decreased upon cisplatin treatment, but SSEA4 mRNA expression increased indicating a
differential regulation of cisplatin at the post-transcriptional level. It is concluded that cis-
platin reduces breast cancer cell survival and induces differentiation of stem/progenitor cell
subpopulations within breast cancer cell lines. These effects indicate the potential of this
drug to target specific chemotherapy-resistant cells within a tumor.
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INTRODUCTION
Breast cancer is one of the most frequent cancers among women
worldwide (Jemal et al., 2010). Much of the difficulty in treating
this disease is due to the heterogeneity of breast tumors, which
consist of a cellular hierarchy similar to the normal breast (Vil-
ladsen et al., 2007; Visvader, 2009; Hassiotou and Geddes, 2012;
Hassiotou et al., 2012; Hassiotou et al., 2013a,b), from cancer cells
with stem cell properties to more differentiated tumor cells (Prat
et al., 2010). Breast cancer stem-like cells (BCSCs) comprise a cell
subpopulation within a tumor that is responsible for the initiation,
progression, chemotherapy resistance, and metastasis of the tumor
(Clarke et al., 2006; Croker and Allan, 2008; Short and Curiel, 2009;
Monteiro and Fodde, 2010; Perou, 2011; Zhao et al., 2011; Dave
et al., 2012; Sampieri and Fodde, 2012). BCSCs originate from nor-
mal mammary stem cells (MaSCs) that have become tumorigenic
due to multiple genetic and epigenetic changes (Wicha et al., 2006;
Shafee et al., 2008). Possessing similar properties to normal MaSCs,
BCSCs proliferate and undergo multi-lineage differentiation,
resulting in the growth and heterogeneous histological appearance
of breast tumors (Turashvili et al., 2007; Levina et al., 2008).
Breast cancer heterogeneity and cellular hierarchy has led
to the identification of five molecular subtypes, which are
distinguished based on their molecular and clinical characteristics,
and pathogenesis (Sotiriou and Pusztai, 2009; Bosch et al., 2010;
Hastak et al., 2010; Al-Ejeh et al., 2011). These include the poorly
characterized claudin-low tumors, the basal-like, human epider-
mal growth factor receptor 2 (HER2) positive, luminal A, and
luminal B tumors.
Luminal breast tumors, represented in vitro by MCF-7 cells,
are more differentiated and are often successfully treated with
chemotherapy, indicating that more differentiated tumors are
more susceptible to treatments. In contrast, the basal-like (e.g.,
MDA-MB-468 cells) and claudin-low subtypes (e.g., MDA-MB-
231 cells) are less differentiated, difficult to treat with poor progno-
sis (Hastak et al., 2010; Holliday and Speirs, 2011). Often, basal-like
and claudin-low tumors lack the estrogen (ER), progesterone (PR),
and HER2 receptors, and are thus triple-negative (Hastak et al.,
2010; Holliday and Speirs, 2011; Tiwary et al., 2011; Byrski et al.,
2012). These tumors are fueled by BCSCs, are highly resistant to
chemotherapy (Hastak et al., 2010; Tiwary et al., 2011), and are
very proliferative with worst survival rates (Bosch et al., 2010;
Hastak et al., 2010; Tiwary et al., 2011). Thus, recent efforts have
been focusing on treatments that may shift the less differenti-
ated BCSCs toward a more differentiated phenotype, making them
more susceptible to treatment options, and eliminating the chance
for recurrence and/or metastasis.
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Cisplatin (cis-diamminedichloroplatinum II) is a metal-based
anti-cancer drug (Rosenberg et al., 1965, 1969) that has been used
extensively in the past four decades for the treatment of many
cancers (Nishiyama et al., 2003; Dickson et al., 2011), including
breast, testicular, ovarian, cervical, head and neck, and small cell
lung cancers (Basu and Krishnamurthy, 2010; Florea and Bus-
selberg, 2011; Pines et al., 2011). Particularly in breast cancer,
cisplatin has been used in combination with other drugs, such
as taxanes, vinca alkaloids, and 5-fluorouracil (Florea and Bus-
selberg, 2011; Holliday and Speirs, 2011), resulting in synergistic
or additive effects. Cisplatin is known to cause DNA damage by
forming Pt-DNA adducts at the 1,2-intrastrand crosslink, leading
to the activation of various signal transduction pathways (Zeidan
et al., 2008; Basu and Krishnamurthy, 2010; Florea and Busselberg,
2011; Wang et al., 2011). However, its exact mechanism of action
and specificity are still not well established. To give insight into
the mechanisms through which cisplatin sensitizes breast cancer
cells to chemotherapy, we examined the effects of cisplatin on cell
phenotype and survival using four human cancer cell lines repre-
senting different molecular and differentiation subtypes of breast
cancer.
MATERIALS AND METHODS
CELL CULTURE
BT-549, MDA-MB-231, MDA-MB-468, and MCF-7 cells (Amer-
ican Type Culture Collection, ATCC) (Table 1) were cultured in
T25 flasks (Corning, Tewksbury, MA, USA) at 37 °C and 5% CO2
in DMEM/F12+ glutamax ™1 (Invitrogen, Carlsbad, CA, USA),
supplemented with 20% fetal bovine serum (FBS) (Serana, WA
Pty Ltd., Bunbury, WA, Australia), and 1% antibiotic-antimycotic
Table 1 | Breast cancer cell lines used.
Cell line Tumor type Tumor
classification
State of
differentiation
BT-549 Papillary invasive
ductal carcinoma
Claudin-low Less differentiated
MDA-MB-231 Adenocarcinoma Claudin-low Least differentiated
MDA-MB-468 Adenocarcinoma Basal-like Differentiated
MCF-7 Adenocarcinoma Luminal A Most differentiated
(Invitrogen). BT-549 and MDA-MB-231 cells were passaged twice
a week, whilst MDA-MB-468 and MCF-7 once a week at 60–70%
cell confluency.
CYTOTOXICITY AND PROLIFERATION ASSAYS
Confluent cell cultures were used for experiments. About 3× 103
cells per 100-µL and per well were seeded in flat bottom 96-well
plates (Sarstedt, Newton, USA). After 24 h, cisplatin was added at
different concentrations (2.5, 5, 10, and 20µM) (Sigma-Aldrich,
St Louis, MO, USA) chosen according to the range used in treat-
ments. After incubation for 24 h, cell viability was assessed by
MTS colorimetric assay, using. Cell Titer 96 ®Aqueous (Promega,
Madison, USA), according to the manufacturer’s instructions.
Cell proliferation was measured using a BrdU colorimetric assay
(Roche Diagnostics, Mannheim, Germany), according to the man-
ufacturer’s instructions. Experiments were done in quadruplicate
in three independent experiments.
IMMUNOFLUORESCENCE MICROSCOPY
Cells were grown on coverslips in 24-well plates (Sarstedt) for
24 h. Cisplatin at 20µM was added and cells were incubated
for 24 h. Cells were then fixed with 1% paraformaldehyde (PFA)
in PBS/2% sucrose, permeabilized with 0.1% Triton in PBS for
30 min, incubated overnight with primary antibodies (Table 2),
and then incubated for 4 h with secondary antibodies (Table 2)
and DAPI (Roche, 1:100) for nuclear staining. Appropriate neg-
ative controls (secondary antibody only) were used. Cells were
imaged using an Olympus 1X71 inverted optical microscope and
an upright Nikon Eclipse 90i microscope.
FLOW CYTOMETRY
Confluent cultures of untreated and 20-µM cisplatin-treated
breast cancer cells were passaged by trypsinization. A day later,
adherent cells were gently scraped and centrifuged at 1200 rpm
for 5 min. Cells were fixed in 1% PFA in PBS/2% sucrose for
20 min at room temperature, and incubated with primary anti-
bodies (Table 2) for 1 h at 4 °C, followed by incubation with
secondary antibodies (Table 2) for 30 min at 4 °C. All intracel-
lular marker antibodies were prepared in permeabilization solu-
tion (0.05% Tween-20 in PBS), whilst surface marker antibodies
Table 2 | Antibodies used.
Antibody Clone Cat. number Company Application
Nestin 3k1 09-0045 Stemgent FC: 1:50
CK18 CY90 MCA1864H AbD Serotec FC: 100µL, IF: 100µL
Smooth muscle actin (SMA) CGA7 Sc-53015 Santa Cruz Biotechnology, Inc. FC: 1:50, IF: 1:10
β-Tubulin – Hybridoma FC: 100µL, IF: 100µL
Stage specific embryonic antigen-4 (SSEA4) MC-813-70 09-0006 Stemgent FC: 1:50
Integrin-α6 (CD49f) GoH3 555735 BD Pharmingen™ FC: 1:4
Alexa Fluor 488 donkey anti-mouse IgG
(H+L)
– A-21202 Invitrogen, USA FC: 1:50, IF: 1:100
Alexa Fluor 488 donkey anti-rabbit IgG (H+L) – A-21206 Invitrogen, USA FC:1:50
FITC rat IgG2a.k R35-95 555843 BD Pharmingen™ FC:1:4
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were prepared in 7% FBS in PBS. Appropriate negative con-
trols (secondary antibody only) were also used. Data acquisi-
tion was done with a FACS Calibur Flow Cytometer (Becton
Dickinson, NJ, USA), and 10,000 events were collected and ana-
lyzed per sample. FlowJo was used for data analysis. Expres-
sion levels were analyzed as the standardized difference in the
Mean Fluorescence Intensity (MFI) between the control and
the test. A MFI threshold was set to distinguish the levels of
protein expression: MFI≤ 20= very low; 21≤MFI≤ 40= low;
41≤MFI≤ 60=medium; 61≤MFI≤ 80= high; 81≤MFI≤ 100
= very high; and MFI≥ 101= extremely high.
QUANTITATIVE REAL-TIME POLYMERASE CHAIN REACTION
Total cellular RNA was extracted using RNAzol® RT (Molecular
Research Center, Inc.). RNA quantity and quality were assessed
with NanoDrop 1000 (NanoDrop, Wilmington, DE, USA). For
each sample, 1µg RNA was treated with RQ1 RNase-Free DNase
(Promega, Madison, USA) and was reverse transcribed using
MMLV (Promega) by incubating at 25 °C (10 min), 55 °C (50 min),
and 70 °C (15 min) using PTC-100 ™Programmable Thermal
Controller (MJ Research Inc.). The RT Reaction Clean-Up MoBio
kit (MoBio Lab Inc., CA, USA) was used for cDNA clean up.
The Brilliant SYBR green quantitative real-time polymerase chain
reaction (qRT-PCR) Master Mix consisting of 5µL of IQ ™SYBR
®Green Supermix (Bio-Rad, CA, USA), 1µL of each forward and
reverse primers for each gene (Table 3), 1µL of H2O and 2µL of
cDNA were used to detect the relative abundance of transcripts.
The conditions for all qRT-PCR reactions were as follows: 10 s at
95 °C followed by 30 s at 54, 55, and 60 °C (Table 3), and 15 s
at 72 °C for 40 cycles. Validation was done by sequencing of the
PCR products, analysis of the melting curves and use of β-actin
as the positive control and non-template sample as the negative
control.
STATISTICAL ANALYSIS
Statistical analysis and graphical exploration of the data were done
in Microsoft Excel. The Student’s paired t -test with a two-tailed
distribution was used to compare cisplatin-treated and untreated
breast cancer cells. The results are presented as mean± SD (MTS
and BrdU) and mean± SEM (flow cytometry and qRT-PCR), as
indicated in the corresponding figure legends. The significance is
shown as follows: ∗p≤ 0.05; ∗∗p≤ 0.0005; ∗∗∗p< 0.0001.
Table 3 | Primers used for RT-PCR.
Gene Forward primer Reverse primer Annealing
temperature ( °C)
SSEA4 5′ TGG ACG GGC
ACA ACT TCA TC 3′
5′ GGG CAG GTT
CTT GGC ACT CT 3′
54
CD49f 5′ ATG GAG GAA
ACC CTG TGG CT 3′
5′ ACG AGA GCT
TGG CTC TTG GA 3′
60
β-Tubulin
6
5′ AGG CTA CGT
GGG AGA CTC G 3′
5′ GCC CTG GGC
ACA TAT TTC T 3′
60
β-Actin 5′ CGG CAT TCA
CGA AAC 3′
5′ GGG CAG TGA
TCT CTT 3′
55
RESULTS
CISPLATIN REDUCES VIABILITY AND PROLIFERATION OF BREAST
CANCER CELLS
Cisplatin showed dose-dependent effects in all tested cell lines.
At lower doses (2.5–5µM), cisplatin enhanced cell viability and
proliferation in BT-549 and MDA-MB-231 cells, whilst a small
decline in viability and proliferation was observed in MDA-MB-
468 and MCF-7 cells. At the doses most commonly reached
A
B
C
D
FIGURE 1 | Cisplatin reduces cell viability and proliferation in breast
cancer cells. (A) BT-549, (B) MDA-MB-231, (C) MDA-MD-468, and (D)
MCF-7 breast cancer cells cultured without or with 20µM cisplatin for 24 h.
The bar charts show the effect of cisplatin at increasing concentrations (2.5,
5, 10, and 20µM) on cell viability and proliferation in the BT-549,
MDA-MB-231, MDA-MD-468, and MCF-7 respectively, which were
determined by MTS (white bars) and BrdU (black bars) assays. Experiments
were done in quadruplicate in three independent experiments. Bars are
presented as mean±SD (n=3). *p≤0.05; **p≤0.0005; ***p≤0.0001.
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in tissues in clinical treatments (10–20µM), significant reduc-
tions in cell viability and proliferation were observed in all cell
lines, but at different rates, ranging 36–51% for cell viability and
36–67% for proliferation (Figures 1A–D). MCF-7 cells, which
are the most differentiated cells used, showed most dramatic
reductions in cell viability at 10 and 20µM cisplatin (49 and
58%, respectively; p< 0.0001), followed by MDA-MB-468 (48
and 51%, respectively; p< 0.0001), MDA-MB-231 (43 and 45%,
respectively; p< 0.0001), and BT-549 (36 and 44%, respectively;
p< 0.0001). Similarly, 5µM caused significant reductions in cell
viability and proliferation, but only in the more differentiated
MDA-MB-468 (9 and 24%, respectively; p< 0.001) and MCF-
7 (9 and 29%, respectively; p< 0.01). Cell proliferative capacity
decreased more than cell viability in the cell lines at 10 and 20µM:
in MCF-7 60 and 74%, respectively (p< 0.0001), in MDA-MB-468
58 and 66%, respectively (p< 0.0001) and in MDA-MB-231 51
and 61%, respectively (p< 0.0001). Exception to this was BT-549
cells, which showed reduction in proliferation that was similar to
the reduction of viability (36 and 45%, respectively; p< 0.0001),
suggesting that the surviving cells may undergo differentiation.
Upon cisplatin treatment, the less differentiated cells displayed a
more differentiated phenotype (Figure 1B); BT-549 cells appeared
more contracted and elongated (Figure 1A), and MDA-MB-231
cells appeared slightly enlarged and elongated (Figure 1B). Mor-
phological changes were not as prominent in the more differen-
tiated MDA-MB-468 and MCF-7 cells. These results demonstrate
that cisplatin treatment caused a reduction in both cell viability
and proliferation by interfering with cellular functions through
unknown mechanisms, with the most prominent effects at the
cisplatin concentrations that are expected in the clinical setting.
CISPLATIN INDUCES BREAST CANCER CELL DIFFERENTIATION
The effect of cisplatin on expression of a variety of key mark-
ers, such as SSEA4, CD49f, nestin, SMA, CK18, and β-tubulin,
was examined using flow cytometry. A cellular hierarchy was
observed in the untreated cell lines (Figures 2A–D). Untreated
BT-549,MDA-MB-231,MDA-MB-468,and MCF-7 cells expressed
stem cell markers (SSEA4, CD49f, nestin), a myoepithelial marker
A 
B 
C 
D 
Untreated 
20 M cisplatin
*
*
*
B
T
-5
4
9
 
M
C
F
-7
 
M
D
A
-M
B
-4
6
8
 
M
D
A
-M
B
-2
3
1
 
0 
20 
40 
60 
CD49f SSEA4 Nestin SMA CK18 Tubulin 
 M
e
a
n
 F
lu
o
re
s
c
e
n
c
e
 I
n
te
n
s
it
y
 
S
ta
n
d
a
rd
is
e
d
 D
if
fe
re
n
c
e
 
-T bulin 
* *
*
0 
20 
40 
60 
80 
100 
120 
CD49f SSEA4 Nestin SMA CK18 Tubulin 
M
e
a
n
 F
lu
o
re
s
c
e
n
c
e
 I
n
te
n
s
it
y
 
S
ta
n
d
a
rd
is
e
d
 D
if
fe
re
n
c
e
 
-Tubulin 
**
*
0 
20 
40 
60 
CD49f SSEA4 Nestin SMA CK18 Tubulin 
M
e
a
n
 F
lu
o
re
s
c
e
n
c
e
 I
n
te
n
s
it
y
 
S
ta
n
d
a
rd
is
e
d
 D
if
fe
re
n
c
e
 
-Tubulin 
*
*
*
0 
20 
40 
60 
80 
CD49f SSEA4 Nestin SMA CK18 Tubulin 
M
e
a
n
 F
lu
o
re
s
c
e
n
c
e
 I
n
te
n
s
it
y
 
S
ta
n
d
a
rd
is
e
d
 D
if
fe
re
n
c
e
 
-Tubulin 
*
CD49f Nestin CK18 
SMA NestinCD49f -Tubulin SSEA4 
CD49f Nestin SMA CK18 -Tubulin SSEA4 
SSEA4 Nestin SMA CK18 
SSEA4 SMA -Tubulin 
CK18 
-Tubulin CD49f 
*
20 M cisplatinUntreatedNegative control
FIGURE 2 | Cisplatin shifts breast cancer cells toward a more
differentiated phenotype. Flow cytometric quantification of CD49f,
SSEA4, nestin, SMA, CK18, and β-tubulin protein expression showed
various levels in four breast cancer cell lines. (A–D) show flow
cytometry histograms of expression of the above markers in BT-549,
MDA-MB-231, MDA-MB-468, and MCF-7 (black dashed line: unstained
control; gray line: FITC-stained untreated breast cancer cells; black line:
FITC-stained 20µM cisplatin-treated breast cancer cells). The bar charts
show quantification of the level of expression based on the mean
fluorescence intensity (MFI) standardized difference of cisplatin-treated
(20µM cisplatin for 24 h) and untreated BT-549, MDA-MB-231,
MDA-MD-468, and MCF-7 breast cancer cells. Bars are presented as
mean fluorescence intensity (MFI) standardized difference±SEM
(n=3). *p≤0.05.
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(SMA), an epithelial marker (CK18) and a microtubule marker
(β-tubulin). These markers were expressed at various levels
depending on the differentiation status of each cell line (Figure 2;
Table 4). BT-549 expressed medium to high levels of β-tubulin,
CD49f, and nestin, but very low levels of SMA and CK18 (Figure 2;
Table 4). MDA-MB-231 cells expressed medium to high levels of
CK18, β-tubulin, CD49f, and SSEA4, whilst SMA and nestin were
expressed at very low levels. In contrast, MDA-MB-468 cells and
MCF-7 expressed CK18 at very high levels, whilst SSEA4, CD49f,
and SMA were expressed at low levels (Table 4). Nestin was highly
expressed in MDA-MB-468, but at low levels in MCF-7. β-Tubulin
was expressed at medium and high levels, respectively, in these cell
lines (Table 4).
Treatment with cisplatin shifted the cellular hierarchy of
these cell lines, causing distinct changes in cell phenotype
and protein expression (Figure 2; Table 4). The stem cell
markers SSEA4 and CD49f were significantly down-regulated
in all the TNBC cell lines, BT-549 (p= 0.023 and p= 0.034,
respectively), MDA-MB-231 (p= 0.018 and p= 0.036, respec-
tively), and MDA-MB-468 (p= 0.03 and p= 0.018, respectively)
(Figures 2A–C; Table 4). A significant reduction in CD49f
expression was also observed in MCF-7 (p= 0.025), but a very
small or negligible change in expression of SSEA4 (Figure 2D;
Table 4). In addition to down-regulation of stem cell mark-
ers, cisplatin induced significant up-regulation of differenti-
ation markers. β-Tubulin was up-regulated in MDA-MB-231
(p= 0.044), MDA-MB-468 (β-tubulin: p= 0.020), and MCF-7
(β-tubulin: p= 0.034), whilst CK18 expression increased signifi-
cantly in MDA-MB-231 (p= 0.045), and only marginally in the
latter two cell lines (Figures 2B–D; Table 4). In BT-549 cells,
SMA (p= 0.014) and β-tubulin (p= 0.020) were up-regulated
(Figure 2A; Table 4). Immunofluorescence imaging confirmed the
increased expression of SMA, CK18, and β-tubulin upon cisplatin
treatment (Figures 3 and 4). These results provided evidence of
differentiation induction in the examined breast cancer cells upon
cisplatin treatment.
DIFFERENTIAL GENE REGULATION BY CISPLATIN AT THE
TRANSCRIPTIONAL AND POST-TRANSCRIPTIONAL LEVELS
To examine the role of cisplatin in gene regulation, CD49f,
SSEA4, and β-tubulin mRNA expression levels were measured
in 20µM cisplatin-treated and untreated cells in two of the
most invasive breast cancer cell lines, BT-549 and MDA-MB-
231, which showed either low or very high protein expression
levels prior to treatment, and were clearly differentiated by cis-
platin. The mRNA expression of β-tubulin was significantly
Table 4 | Breast cancer cell characterization and effects of cisplatin on protein expression.
Cell line Cell type Markers No drug (MFI) Cisplatin (MFI) Up/down-regulation (%)
BT-549 Stem cells SSEA4 22.2 7.2 ↓ (67.6)
CD49f 60 27 ↓ (54.8)
Progenitor cells Nestin 45 21 ↓ (52.3)
Differentiated cells SMA 7.8 17.9 ↑ (129.5)
CK18 7 2 ↓ (71.2)
β-Tubulin 66 148.6 ↑ (125.2)
MDA-MB-231 Stem cells SSEA4 518.2 205.3 ↓ (60.4)
CD49f 53 24 ↓ (55)
Progenitor cells Nestin 35.8 45.5 ↑ (27)
Differentiated cells SMA 9.7 6.2 ↓ (36)
CK18 41.2 45.4 ↑ (10.2)
β-Tubulin 49.6 83.6 ↑ (68.5)
MDA-MB-468 Stem cells SSEA4 6.5 4 ↓ (38.5)
CD49f 27 15 ↓ (44.4)
Progenitor cells Nestin 81 65 ↓ (19.6)
Differentiated cells SMA 25 13 ↓ (48)
CK18 161.8 262.4 ↑ (62.2)
β-Tubulin 52.9 82 ↑ (55)
MCF-7 Stem cells SSEA4 8.02 7.02 ↓ (12.5)
CD49F 27.2 15.8 ↓ (41.9)
Progenitor cells Nestin 30.3 29.4 ↓ (3)
Differentiated cells SMA 14.2 10.2 ↓ (28.2)
CK18 173.1 224 ↑ (29.4)
β-Tubulin 74.9 141 ↑ (88.3)
MFI, mean fluorescence intensity; ESC, embryonic stem cell; SSEA4, stage specific embryonic antigen-4; CD49f, integrin subunit-α6; SMA, smooth muscle actin;
CK18, cytokeratin 18.
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FIGURE 3 | Cisplatin influences expression of differentiation markers in BT-549 cells. Differentiation markers SMA and β-tubulin were up-regulated upon
treatment with 20µM cisplatin in BT-549 cells. DAPI nuclear stain was used to stain the nucleus (blue), whilst all other markers are shown in green. Scale bars:
100µm.
increased upon cisplatin treatment in both BT-549 (p= 0.043)
and MDA-MB-231 (p= 0.021) (Figure 5). mRNA expression of
CD49f significantly decreased with cisplatin treatment (p= 0.036
and p= 0.034, respectively) (Figure 5), whilst at lower cisplatin
dose (5µM) an increase in the mRNA expression of CD49f
was observed (MDA-MB-231: p= 0.014) (Figure 6). The mRNA
expression pattern for both β-tubulin and CD49f was con-
sistent with the protein expression pattern. However, SSEA4
mRNA expression was significantly up-regulated in cisplatin-
treated BT-549 (p= 0.019) and MDA-MB-231 cells (p= 0.022)
(Figure 5), which was contrary to the protein expression pat-
tern. This suggests that cisplatin may differentially regulate gene
expression, with potential post-transcriptional effects for certain
genes.
DISCUSSION
Recent efforts are focusing on the development of breast can-
cer treatments that specifically target the cancer stem cells
(CSCs), which are responsible for tumor progression, metastasis,
and recurrence. Given the resistance of CSCs to chemotherapy,
successful treatments must first induce CSC differentiation to
make them more susceptible to the killing effects of anti-cancer
drugs. Here, we demonstrate cisplatin-inducted differentiation of
common cell lines representing different subtypes of breast can-
cer, including TNBCs, which are the most aggressive and highly
populated by CSCs. This effect of cisplatin was delivered via down-
regulation of the stem cell markers CD49f and SSEA4, and subse-
quent cytotoxicity resulting in marked reduction in cell viability
and proliferation. These findings give insight into the cellular hier-
archy of breast tumors and suggest a novel mechanism of action
for cisplatin that first differentiates and then kills breast cancer
cells.
Cytotoxicity assays of cisplatin treatment revealed a cytotoxic
effect a high doses (10 and 20µM). The observed increase in cell
proliferation at low cisplatin doses suggests that the CSCs, which
are the most proliferative within a tumor, are not killed, and this
needs to be taken into consideration in future cisplatin treatments.
At high doses, cisplatin probably kills the tumor cells by interfer-
ing with cellular structure and function at the DNA level (Basu
and Krishnamurthy, 2010), as has been shown previously. At the
same time, cisplatin appeared to regulate gene expression, and
therefore interfere with the stage of cellular differentiation, both
Frontiers in Oncology | Women’s Cancer June 2013 | Volume 3 | Article 134 | 6
Prabhakaran et al. Cisplatin-induced differentiation of breast cancer cells
FITC DAPI Merged FITC DAPI Merged 
C
K
1
8
 
S
M
A
 
N
e
g
a
ti
v
e
 
c
o
n
tr
o
l 
-t
u
b
u
li
n
 
MDA-MB-468 
Untreated 
MDA-MB-468  
20 M cisplatin
100 m 100 m 100 m 
100 m 100 m 100 m 
100 m 100 m 100 m 
100 m 100 m 100 m 
100 m 100 m 100 m 
100 m 100 m 100 m 
100 m 100 m 100 m 
100 m 100 m 100 m 
FIGURE 4 | Cisplatin influences expression of differentiation markers in MDA-MB-468. Differentiation markers CK18 and β-tubulin were up-regulated upon
treatment with 20µM cisplatin in MDA-MB-468 cells. DAPI nuclear stain was used to stain the nucleus (blue), whilst all other markers are shown in green.
Scale bars: 100µm.
at the mRNA and protein levels. Interestingly, the response to cis-
platin treatment varied between the different cell lines tested, and
for the different cisplatin doses examined. This is in agreement
with previous studies showing that some tumor cells require high
cisplatin doses, whilst other tumor cells require small doses to be
killed (Foroodi et al., 2009; Wang et al., 2011; Milrot et al., 2012).
Low, non-toxic dosage may have a different effect without causing
cell death. This differential response suggests that cisplatin may
act in a tumor-specific manner, depending on the properties and
cellular hierarchy manifested by each tumor. This led us to inves-
tigate how cisplatin affects the cellular hierarchy and phenotypes
of breast cancer cell lines.
Flow cytometric analysis of protein expression revealed a novel
cellular hierarchy in the breast cancer cell lines examined which
differed depending on the cell line. This was consistent with the
previously suggested breast cancer heterogeneity (Clarke et al.,
2006). The stem cell markers SSEA4 and CD49f were highly
expressed in the more aggressive CSC-enriched and triple-negative
cell lines, whereas the differentiation markers CK18 and β-tubulin
were highly expressed in the more differentiated cell lines. It is of
interest that the MDA-MB-468, a basal-like triple-negative line, is
more differentiated than other triple-negative lines, such as BT-549
and MDA-MB-231.
Cisplatin treatment shifted this cellular hierarchy toward more
differentiated cells by selectively targeting and down-regulating the
stem cell markers CD49f and SSEA4 by 50–70% in the more inva-
sive breast cancer cell lines (BT-549 and MDA-MB-231), whilst
up-regulating the differentiation markers CK18, SMA, and β-
tubulin by 10–130% (Figure 2; Table 4). High CD49f and SSEA4
expression has been associated with low levels of tumor differen-
tiation and reduced survival in breast cancer patients, and is often
more prevalent in TNBCs (Zeidan et al., 2008; Stagg and Pommey,
2009; Meyer et al., 2010; Sanges and Cosma, 2010). CD49f and
SSEA4 along with other surface markers, such as CD24, CD44,
CD133, have been commonly used for the detection of CSCs in
solid tumors, including human breast, brain, colon, and ovarian
cancer (Zhou et al., 2009), as well as for categorizing breast can-
cer molecular subtypes (Hergueta-Redondo et al., 2008; Nakshatri
et al., 2009; Stagg and Pommey, 2009). In contrast, the differenti-
ation marker CK18 is highly expressed in the normal mammary
glands (more than 90% cells), and its loss has been correlated with
high tumor grade (Woelfle et al., 2004). These findings clearly show
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FIGURE 5 | Effects of cisplatin on mRNA expression of β-tubulin,
CD49f, and SSEA4 in breast cancer cells. Individual PCR reactions
were normalized against internal positive control (β-actin) and plotted as
the mRNA relative expression for both untreated and cisplatin-treated
BT-549 (A) and MDA-MB-231 (B) breast cancer cells. Cells were
incubated with 20µM cisplatin for 24 h. Experiments were done in
duplicates in three independent experiments. Bars are presented as
mean±SEM. *p≤0.05.
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FIGURE 6 | Comparison of cisplatin effect on mRNA expression of
CD49f, a stem cell marker, at low and high cisplatin doses in breast
cancer cells. Individual PCR reactions were normalized against internal
positive control (β-actin) and plotted as the mRNA relative expression for
both untreated and cisplatin-treated BT-549 and MDA-MB-231 breast
cancer cells. Cells were incubated with 5 and 20µM cisplatin for 24 h.
Experiments were done in duplicates in three independent experiments.
Bars are presented as mean±SEM. *p≤0.05.
that cisplatin treatment influenced gene expression in the breast
cancer cell lines tested to shift them toward a more differentiated
phenotype.
The current anti-cancer drug therapies are undergoing a huge
shift from cytotoxic-based to differentiation-inducing therapies,
as many types of tumors acquire further resistance, recur, and/or
metastasize after treatment due to survival of the resistant CSCs
(Prat et al., 2010). The general rule of tumor cell differentiation
therapy is to force maturation of less differentiated CSCs or can-
cer progenitor cells into specific lineages, which in turn reduces
proliferation capacity and tumorigenicity (Hadnagy et al., 2008).
Based on our findings, we propose that cisplatin not only induces
symmetrical differentiation, but also asymmetrical differentiation,
shifting BT-549 cells toward a myoepithelial phenotype,and MDA-
MB-231 and MDA-MB-468 cells toward a luminal phenotype.
The fate of switching from one cell type to another (myoep-
ithelial to epithelial cell type and vice-versa) may depend on
the more dominating or prominent progenitor cell type present
in each cell line. However, extensive study is required to fur-
ther confirm the mechanism of cisplatin-mediated induction of
differentiation.
A possible mechanism of cisplatin-induced differentiation in
breast cancer cells is direct interference of the cis-platinum com-
pound with the DNA sequence at the reactive nuclear sites, causing
conformational changes and inhibiting transcription, which even-
tually leads to cancer cell death. This can be correlated with
various levels of binding capacity to target sites in the nuclear
DNA of the tumor cell. Even partial binding of cisplatin to the
DNA sequence, 1,3-intrastand GpG crosslink, or other unknown
crosslink patterns, can trigger changes in gene expression and cell
function. A second mechanism of cisplatin action could involve
binding of the cis-platinum compound to non-DNA targets. This
is supported by a previous study demonstrating that <1% of
the cis-platinum compound binds and form adducts with the
nuclear DNA of the tumor cell, while 75–85% of it forms cova-
lent bonds with thiol peptides, proteins, RNAs, and other cellular
constituents (Cepeda et al., 2007). Other studies have also shown
that platinum compounds can bind to cellular proteins such as the
zing-fingers, tubulin as well as actin (Cepeda et al., 2007; Wexsel-
blatt et al., 2012). Consistent with this, we show that cisplatin
clearly affects the cytoskeleton through morphological changes as
well as clear changes in the cytoskeleton proteins β-tubulin, CK18,
and SMA (Figures 3 and 4). Binding of cisplatin to these proteins
may lead to structural conformation changes that restrict move-
ment of cell proliferation-controlling transcription factors to the
nucleus and attachment to their target promoters (Nguyen et al.,
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FIGURE 7 | A proposed model of cellular hierarchy in breast cancer cells
and how it is influenced by cisplatin. The diagram illustrates a possible
mechanism of cisplatin effects in breast cancer cells. Cancer stem cells can
differentiate, potentially through progenitor steps, into a more mature
epithelial phenotype, luminal, or myoepithelial, which has lost or possesses
limited proliferative potential. As the more differentiated cells are more
susceptible to chemotherapy, this push of differentiation may assist in the
management and/or treatment of breast cancer.
2010). Figure 7 illustrates a proposed model based on our find-
ings which depicts the role of cisplatin in differentiating breast
cancer cells.
In addition to effects of cisplatin at the protein level, we demon-
strated differential gene regulation at the mRNA level. CD49f
and β-tubulin mRNA and protein expression were affected in
a similar way by cisplatin in BT-549 and MDA-MB-231 cells,
suggesting that cisplatin’s point of interference was at the DNA
sequence. However, SSEA4 expression was influenced differently
at the mRNA and protein levels by cisplatin treatment, with
decrease in protein expression, but an increase in mRNA expres-
sion. This suggests that this drug may influence certain genes
differentially at the post-transcriptional or post-translational lev-
els without affecting the DNA sequence, which could be linked
to epigenetic regulation (Hadnagy et al., 2008). This is fur-
ther supported by a recent study showing that SSEA mark-
ers are among the most epigenetically accessible and can in
turn mediate the expression of chromatin remodeling factors
that are accountable for the principal epigenetic modifications
(Sanges and Cosma, 2010). Taken together, these results suggest
that in the tumor environment cisplatin may activate binding
of other components to DNA, resulting in disruption of DNA
transcription.
CONCLUSION
Breast tumors are characterized by a cellular hierarchy, similar to
the healthy resting and lactating breast (Hassiotou et al., 2012; Has-
siotou et al., 2013a,b), containing CSCs and more differentiated
cancer cells, each with different susceptibility toward various anti-
cancer drugs. Cisplatin seems to shift this hierarchy toward more
differentiated cells that are less proliferative. Although the mecha-
nism of action of cisplatin still remains elusive, we demonstrated
differential effects at the mRNA and protein levels for some genes,
suggesting involvement of both or either of epigenetic mechanisms
and recruitment of other cellular components that influence gene
transcription and/or translation. Further studies are needed to
give insight into how cisplatin acts on tumor cells, and whether
and how it may influence their normal cell counterparts.
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